101 related articles for article (PubMed ID: 2109926)
1. Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction.
Khan MI; Hackett DR; Andreotti F; Davies GJ; Regan T; Haider AW; McFadden E; Halson P; Maseri A
Am J Cardiol; 1990 May; 65(16):1051-6. PubMed ID: 2109926
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Hackett D; Andreotti F; Haider AW; Brunelli C; Shahi M; Fussell A; Buller N; Foale R; Lipkin D; Caponnetto S
Am J Cardiol; 1992 Jun; 69(17):1393-8. PubMed ID: 1590225
[TBL] [Abstract][Full Text] [Related]
3. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction.
Tebbe U; von Essen R; Smolarz A; Limbourg P; Rox J; Rustige J; Vogt A; Wagner J; Meyer-Sabellek W; Neuhaus KL
Am J Cardiol; 1993 Sep; 72(7):518-24. PubMed ID: 8362764
[TBL] [Abstract][Full Text] [Related]
4. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
[TBL] [Abstract][Full Text] [Related]
5. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.
Tebbe U; Tanswell P; Seifried E; Feuerer W; Scholz KH; Herrmann KS
Am J Cardiol; 1989 Sep; 64(8):448-53. PubMed ID: 2505604
[TBL] [Abstract][Full Text] [Related]
6. Effect of the initial bolus volume of recombinant tissue-type plasminogen activator on coronary recanalization and infarct size in Japanese acute myocardial infarction patients. Kumamoto University Myocardial Infarction Study (KUMIS) Group.
Ogawa H; Yasue H; Oshima S; Ogata Y; Numata Y; Fujimoto K; Imoto N; Saito T; Hokamura Y; Takahashi T
Jpn Circ J; 1995 Oct; 59(10):663-72. PubMed ID: 8558750
[TBL] [Abstract][Full Text] [Related]
7. Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction.
Tranchesi B; Chamone DF; Cobbaert C; Van de Werf F; Vanhove P; Verstraete M
Am J Cardiol; 1991 Jul; 68(2):161-5. PubMed ID: 1829574
[TBL] [Abstract][Full Text] [Related]
8. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
[TBL] [Abstract][Full Text] [Related]
9. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
[TBL] [Abstract][Full Text] [Related]
10. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.
Kalbfleisch J; Thadani U; LittleJohn JK; Brown G; Magorien R; Kutcher M; Taylor G; Maddox WT; Campbell WB; Perry J
Am J Cardiol; 1992 May; 69(14):1120-7. PubMed ID: 1575179
[TBL] [Abstract][Full Text] [Related]
12. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
de Bono DP
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
[TBL] [Abstract][Full Text] [Related]
13. [Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction].
Gao R
Zhonghua Xin Xue Guan Bing Za Zhi; 1991 Aug; 19(4):228-30, 267-8. PubMed ID: 1813288
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration.
McKendall GR; Attubato MJ; Drew TM; Feit F; Sharaf BL; Thomas ES; Teichman S; McDonald MJ; Williams DO
J Am Coll Cardiol; 1991 Dec; 18(7):1774-8. PubMed ID: 1960329
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction.
Purvis JA; Trouton TG; Roberts MJ; McKeown P; Mulholland MG; Dalzell GW; Wilson CM; Patterson GC; Webb SW; Khan MM
Am J Cardiol; 1991 Dec; 68(17):1570-4. PubMed ID: 1746456
[TBL] [Abstract][Full Text] [Related]
16. An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy.
Bleich SD; Adgey AA; McMechan SR; Love TW
Am Heart J; 1998 Oct; 136(4 Pt 1):741-8. PubMed ID: 9778080
[TBL] [Abstract][Full Text] [Related]
17. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Van de Werf F; Arnold AE
BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
[TBL] [Abstract][Full Text] [Related]
18. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
Gao R; Chen J; Kou W; Yao K; Xu Y; Lu Z; Yu Q; Tao P; Ma J; Zhu J
Chin Med Sci J; 1991 Sep; 6(3):132-5. PubMed ID: 1793874
[TBL] [Abstract][Full Text] [Related]
19. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
Williams DO; Borer J; Braunwald E; Chesebro JH; Cohen LS; Dalen J; Dodge HT; Francis CK; Knatterud G; Ludbrook P
Circulation; 1986 Feb; 73(2):338-46. PubMed ID: 3080261
[TBL] [Abstract][Full Text] [Related]
20. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
